190 related articles for article (PubMed ID: 38671240)
1. Bispecific T cell engager therapy for refractory rheumatoid arthritis.
Bucci L; Hagen M; Rothe T; Raimondo MG; Fagni F; Tur C; Wirsching A; Wacker J; Wilhelm A; Auger JP; Pachowsky M; Eckstein M; Alivernini S; Zoli A; Krönke G; Uderhardt S; Bozec A; D'Agostino MA; Schett G; Grieshaber-Bouyer R
Nat Med; 2024 Apr; ():. PubMed ID: 38671240
[TBL] [Abstract][Full Text] [Related]
2. Blinatumomab, a Bispecific T-cell Engager (BiTE(®)) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications.
Zhu M; Wu B; Brandl C; Johnson J; Wolf A; Chow A; Doshi S
Clin Pharmacokinet; 2016 Oct; 55(10):1271-1288. PubMed ID: 27209293
[TBL] [Abstract][Full Text] [Related]
3. Blinatumomab: A First-in-Class Bispecific T-Cell Engager for Precursor B-Cell Acute Lymphoblastic Leukemia.
Buie LW; Pecoraro JJ; Horvat TZ; Daley RJ
Ann Pharmacother; 2015 Sep; 49(9):1057-67. PubMed ID: 26041811
[TBL] [Abstract][Full Text] [Related]
4. Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy.
Goebeler ME; Bargou R
Leuk Lymphoma; 2016 May; 57(5):1021-32. PubMed ID: 27050240
[TBL] [Abstract][Full Text] [Related]
5. A Systematic Review of Blinatumomab in the Treatment of Acute Lymphoblastic Leukemia: Engaging an Old Problem With New Solutions.
Halford Z; Coalter C; Gresham V; Brown T
Ann Pharmacother; 2021 Oct; 55(10):1236-1253. PubMed ID: 33435716
[TBL] [Abstract][Full Text] [Related]
6. Blinatumomab-induced T cell activation at single cell transcriptome resolution.
Huo Y; Sheng Z; Lu DR; Ellwanger DC; Li CM; Homann O; Wang S; Yin H; Ren R
BMC Genomics; 2021 Mar; 22(1):145. PubMed ID: 33648458
[TBL] [Abstract][Full Text] [Related]
7. Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemia.
Le Jeune C; Thomas X
Drug Des Devel Ther; 2016; 10():757-65. PubMed ID: 26937176
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of bispecific T-cell engager blinatumomab and the potential to improve leukemia-free survival in B-cell acute lymphoblastic leukemia.
Ribera JM
Expert Rev Hematol; 2017 Dec; 10(12):1057-1067. PubMed ID: 29082835
[TBL] [Abstract][Full Text] [Related]
9. Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies.
Viardot A; Locatelli F; Stieglmaier J; Zaman F; Jabbour E
Ann Hematol; 2020 Oct; 99(10):2215-2229. PubMed ID: 32856140
[TBL] [Abstract][Full Text] [Related]
10. Long-term survival of patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab.
Topp MS; Gökbuget N; Zugmaier G; Stein AS; Dombret H; Chen Y; Ribera JM; Bargou RC; Horst HA; Kantarjian HM
Cancer; 2021 Feb; 127(4):554-559. PubMed ID: 33141929
[TBL] [Abstract][Full Text] [Related]
11. A Novel bispecific T-cell engager (BiTE) targeting CD22 and CD3 has both in vitro and in vivo activity and synergizes with blinatumomab in an acute lymphoblastic leukemia (ALL) tumor model.
Meckler JF; Levis DJ; Vang DP; Tuscano JM
Cancer Immunol Immunother; 2023 Sep; 72(9):2939-2948. PubMed ID: 37247022
[TBL] [Abstract][Full Text] [Related]
12. Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study.
Goebeler ME; Knop S; Viardot A; Kufer P; Topp MS; Einsele H; Noppeney R; Hess G; Kallert S; Mackensen A; Rupertus K; Kanz L; Libicher M; Nagorsen D; Zugmaier G; Klinger M; Wolf A; Dorsch B; Quednau BD; Schmidt M; Scheele J; Baeuerle PA; Leo E; Bargou RC
J Clin Oncol; 2016 Apr; 34(10):1104-11. PubMed ID: 26884582
[TBL] [Abstract][Full Text] [Related]
13. Treatment of Relapsed B/T-cell Mixed Phenotype Acute Leukemia With Blinatumomab.
Abdo Y; Gibson GD; Jain SP; Milner CP; Hilal T
Cureus; 2023 Jun; 15(6):e40661. PubMed ID: 37485162
[TBL] [Abstract][Full Text] [Related]
14. Safety and Efficacy of Blinatumomab in Japanese Adult and Pediatric Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: Final Results from an Expansion Cohort.
Goto H; Ogawa C; Iida H; Horibe K; Oh I; Takada S; Maeda Y; Minami H; Nakashima Y; Morris JD; Kormany W; Chen Y; Miyamoto T
Acta Haematol; 2022; 145(6):592-602. PubMed ID: 35790143
[TBL] [Abstract][Full Text] [Related]
15. Blinatumomab for Acute Lymphoblastic Leukemia: The First Bispecific T-Cell Engager Antibody to Be Approved by the EMA for Minimal Residual Disease.
Ali S; Moreau A; Melchiorri D; Camarero J; Josephson F; Olimpier O; Bergh J; Karres D; Tzogani K; Gisselbrecht C; Pignatti F
Oncologist; 2020 Apr; 25(4):e709-e715. PubMed ID: 32297447
[TBL] [Abstract][Full Text] [Related]
16. Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia.
Portell CA; Wenzell CM; Advani AS
Clin Pharmacol; 2013; 5(Suppl 1):5-11. PubMed ID: 23671399
[TBL] [Abstract][Full Text] [Related]
17. Recent advances on blinatumomab for acute lymphoblastic leukemia.
Zhao J; Song Y; Liu D
Exp Hematol Oncol; 2019; 8():28. PubMed ID: 31709129
[TBL] [Abstract][Full Text] [Related]
18. Current and future role of bispecific T-cell engagers in pediatric acute lymphoblastic leukemia.
Algeri M; Del Bufalo F; Galaverna F; Locatelli F
Expert Rev Hematol; 2018 Dec; 11(12):945-956. PubMed ID: 30358451
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia.
Topp MS; Gökbuget N; Zugmaier G; Klappers P; Stelljes M; Neumann S; Viardot A; Marks R; Diedrich H; Faul C; Reichle A; Horst HA; Brüggemann M; Wessiepe D; Holland C; Alekar S; Mergen N; Einsele H; Hoelzer D; Bargou RC
J Clin Oncol; 2014 Dec; 32(36):4134-40. PubMed ID: 25385737
[TBL] [Abstract][Full Text] [Related]
20. Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab.
Schlegel P; Lang P; Zugmaier G; Ebinger M; Kreyenberg H; Witte KE; Feucht J; Pfeiffer M; Teltschik HM; Kyzirakos C; Feuchtinger T; Handgretinger R
Haematologica; 2014 Jul; 99(7):1212-9. PubMed ID: 24727818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
